Results from the phase III CheckMate -577 trial demonstrated that adjuvant treatment with Opdivo (nivolumab) showed a statistically significant and clinically meaningful improvement in disease-free survival, the trial’s primary endpoint, compared to placebo in patients with esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiation therapy and tumor resection.
In the 1970s, when E. Donnall Thomas was researching bone marrow transplantation, Fred Hutchinson Cancer Center started a database of transplant recipients.
